Clustering data with hclust algorithm for Metabolomic and lipidomic profiles in response to exogenous insulin and GLP-1 infusions during prolonged fasting (Study ST000107)
LCMS Positive ion mode (Analysis AN000177)Metabolite | Structure | F1 | F2 | F3 | F4 | F5 | F6 | F7 | F8 | F9 | F10 | F11 | F12 | F13 | F14 | F15 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2-Arachidonoyl Glycerol | ME659981 | 0.89 | 1.34 | 1.14 | 1.05 | 1.78 | 0.81 | 0.41 | 0.42 | 0.36 | 0.30 | 2.73 | 1.27 | 4.17 | 1.46 | 0.74 |
2-Linoleoyl Glycerol | ME659979 | 0.95 | 0.86 | 0.65 | 1.47 | 1.19 | 2.29 | 0.77 | 0.88 | 0.87 | 0.61 | 0.59 | 0.49 | 0.49 | 0.61 | 1.93 |
2-Oleoyl Glycerol | ME659977 | 0.69 | 0.64 | 0.58 | 1.19 | 1.06 | 2.26 | 0.67 | 0.80 | 0.73 | 0.57 | 0.76 | 0.86 | 0.81 | 0.89 | 2.78 |
1-Arachidonoyl Glycerol | ME659980 | 1.24 | 0.85 | 1.52 | 1.36 | 1.53 | 1.19 | 0.65 | 0.87 | 0.61 | 0.62 | 1.56 | 0.88 | 1.89 | 0.93 | 0.87 |
Docosahexaenoyl Ethanolamide | ME659990 | 1.00 | 0.99 | 1.00 | 0.91 | 1.35 | 0.97 | 0.72 | 0.78 | 0.75 | 0.71 | 1.36 | 1.56 | 1.73 | 1.65 | 1.10 |
1-Linoleoyl Glycerol | ME659978 | 0.62 | 0.29 | 0.56 | 0.90 | 0.59 | 1.47 | 1.19 | 1.63 | 1.42 | 0.83 | 0.38 | 0.55 | 0.44 | 0.74 | 0.85 |
PGF2a Ethanolamide | ME659991 | 0.85 | 0.67 | 0.66 | 0.62 | 0.46 | 1.34 | 1.38 | 1.22 | 1.07 | 1.07 | 0.69 | 0.58 | 0.75 | 0.87 | 0.93 |
1-Oleoyl Glycerol | ME659976 | 0.85 | 0.33 | 0.99 | 1.51 | 0.88 | 1.67 | 1.10 | 1.11 | 0.68 | 0.80 | 0.71 | 0.72 | 0.81 | 0.85 | 1.57 |
Docosatetraenoyl Ethanolamide | ME659989 | 1.00 | 0.51 | 1.00 | 0.70 | 0.44 | 1.56 | 0.95 | 0.85 | 0.70 | 0.87 | 1.19 | 1.42 | 0.97 | 1.07 | 1.94 |
Stearoyl Ethanolamide | ME659983 | 0.59 | 0.49 | 0.76 | 0.75 | 0.98 | 1.48 | 0.99 | 1.00 | 0.85 | 1.07 | 1.07 | 0.98 | 0.92 | 1.43 | 1.10 |
Linoleoyl Ethanolamide | ME659985 | 0.94 | 0.86 | 0.95 | 0.72 | 0.77 | 1.17 | 0.95 | 0.98 | 0.88 | 0.88 | 1.20 | 1.30 | 1.37 | 1.14 | 1.07 |
Palmitoyl Ethanolamide | ME659982 | 0.96 | 0.95 | 1.01 | 0.91 | 0.80 | 1.20 | 0.85 | 1.05 | 0.97 | 1.05 | 1.03 | 0.95 | 1.01 | 1.16 | 0.87 |
a-Linolenoyl Ethanolamide | ME659986 | 1.32 | 1.11 | 1.11 | 0.75 | 0.83 | 1.56 | 0.87 | 0.82 | 0.88 | 0.78 | 1.26 | 0.94 | 1.29 | 0.62 | 0.94 |
Arachidonoyl Ethanolamide | ME659988 | 1.31 | 1.01 | 1.25 | 0.83 | 0.44 | 1.31 | 1.05 | 1.01 | 1.00 | 0.93 | 0.75 | 0.81 | 0.81 | 0.67 | 1.36 |
Dihomo-g-Linolenoyl Ethanolamide | ME659987 | 1.05 | 1.01 | 1.54 | 1.11 | 0.77 | 1.29 | 0.88 | 0.79 | 0.83 | 0.82 | 1.26 | 1.08 | 0.85 | 0.89 | 1.43 |
Oleoyl Ethanolamide | ME659984 | 1.12 | 0.89 | 1.20 | 0.95 | 0.63 | 1.32 | 0.94 | 0.94 | 0.77 | 0.95 | 0.99 | 1.06 | 1.00 | 0.85 | 1.50 |
Factors:
F1 | Treatment:Early ITT Infusion Study | Timepoint:0 mins |
F2 | Treatment:Early ITT Infusion Study | Timepoint:10 mins |
F3 | Treatment:Early ITT Infusion Study | Timepoint:120 mins |
F4 | Treatment:Early ITT Infusion Study | Timepoint:30 mins |
F5 | Treatment:Early ITT Infusion Study | Timepoint:60 mins |
F6 | Treatment:GLP1/Late GTT | Timepoint:0 mins |
F7 | Treatment:GLP1/Late GTT | Timepoint:10 mins |
F8 | Treatment:GLP1/Late GTT | Timepoint:120 mins |
F9 | Treatment:GLP1/Late GTT | Timepoint:30 mins |
F10 | Treatment:GLP1/Late GTT | Timepoint:60 mins |
F11 | Treatment:Late ITT Infusion Study | Timepoint:0 mins |
F12 | Treatment:Late ITT Infusion Study | Timepoint:10 mins |
F13 | Treatment:Late ITT Infusion Study | Timepoint:120 mins |
F14 | Treatment:Late ITT Infusion Study | Timepoint:30 mins |
F15 | Treatment:Late ITT Infusion Study | Timepoint:60 mins |